Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Genetics
- Microbiology
- Signs and Symptoms-Clinical Findings
- Chronic Disease
- Cancer Clinic
- Endoscopy
- Urology Cases
- Radiology Cases
Abstract
Citation: Ann Clin Case Rep. 2017;2(1):1251.DOI: 10.25107/2474-1655.1251
Metastatic Melanoma Responding to Combination Chemotherapy and Immunotherapy after Progression on Ipilimumab and Nivolumab Immunotherapy
Elen Vettus, David Draper and Michael A Davies
Department of Chemotherapy, Oncology and Haematology Clinic, North Estonia Medical Center, Estonia
Department of Medical Oncology, Tri Health Cancer Institute, USA
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, USA
*Correspondance to: Michael A Davies
PDF Full Text Case Report | Open Access
Abstract:
We report the case of a patient with stage IV M1c melanoma that developed symptomatic disease progression after treatment with combination immunotherapy (ipilimumab with nivolumab). The patient was subsequently treated with nab-paclitaxel chemotherapy and pembrolizumab and had a rapid and dramatic clinical response. The case illustrates that clinical responses are possible after progression on combination immunotherapy.
Keywords:
Metastatic melanoma; Nab-paclitaxel; Pembrolizumab; Ipilimumab; Nivolumab; Resistance
Cite the Article:
Vettus E, Draper D, Davies MA. Metastatic Melanoma Responding to Combination Chemotherapy and Immunotherapy after Progression on Ipilimumab and Nivolumab Immunotherapy. Ann Clin Case Rep. 2017; 2: 1251.
